Inari Medical Inc

NARI

Equity

ISIN US45332Y1091 / Valor 52764794

NASDAQ (2024-11-21)

USD 49.75+1.53%

Inari Medical Inc
UMushroom community rating:

0.00 0 votes No rating yet

NegativeNeutralPositive

About company

Inari Medical Inc is a company that specializes in developing medical devices to treat venous diseases, specifically focusing on critical vessels affected by Pulmonary Embolism (PE) and Deep Vein Thrombosis (DVT). Their innovative tools are designed to provide effective treatment options for patients suffering from these conditions.

Summarized from source with an LLMView SourceSector: Healthcare

Revenue Growth

Inari Medical Inc. reported revenue of $119.0 million for the second quarter of 2023. The increase over the prior year quarter was driven primarily by an expansion in sales territories, opening of new accounts, increased adoption of procedures, and global commercial expansion.

Gross Profit

Gross profit for Inari Medical Inc. was $105.2 million for the second quarter of 2023. This figure reflects a strong performance compared to the same period in the previous year, showcasing the company's effective cost management and revenue growth strategies.

Operating Expenses

Operating expenses for Inari Medical Inc. were $106.7 million for the second quarter of 2023. The increase was mainly driven by personnel-related expenses, including commissions and share-based compensation associated with increased headcount to fund the expansion of various organizational functions.

Net Income

Inari Medical Inc. reported a net income of $2.1 million for the second quarter of 2023. This resulted in a net income per share of $0.04 on a weighted-average basic count of 57.2 million and $0.04 on a weighted-average diluted share count of 58.5 million, respectively.

Full Year Revenue Guidance

Inari Medical Inc. raised its full year 2024 revenue guidance to a range of $594.5 million to $604.5 million, reflecting growth of approximately 20.5% to 22.5% over 2023. The company continues to expect to reach sustained operating profitability in the first half of 2025.

Summarized from source with an LLMView Source

Key figures

-13.8%1Y

-43.5%3Y

%5Y

Performance

51.8%1Y

56.6%3Y

57.4%5Y

Volatility